# MCPP
*Source: https://psychonautwiki.org/wiki/MCPP*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 15 mg
- Light: 20 - 50 mg
- Common: 50 - 120 mg
- Strong: 120 - 150 mg
- Heavy: 150 mg +

**Duration:**
- Onset: 20 - 60 minutes
- Come up: 20 - 60 minutes
- Peak: 2 - 4 hours
- Offset: 3 - 8 hours

**meta-Chlorophenylpiperazine** (also known as **mCPP** ) is a stimulant drug of the phenylpiperazine class. It was first synthesized as one in a series of potential novel [antihistamines](https://psychonautwiki.org/wiki/Anti-histamines) by Thomas H. Wicker Jr. in 1951 as part of his doctoral work at the University of Florida. Unlike many other stimulants like [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) , mCPP is generally considered to be unpleasant. mCPP is notable for inducing anxiety , and causing migraines and severe headaches. mCPP is occasionally encountered as an adulterant in street [MDMA](https://psychonautwiki.org/wiki/MDMA) .

## Chemistry

mCPP is a drug in the phenylpiperazine class. On the *meta* -position of the phenyl group, there is a chlorine atom.

## Pharmacology

mCPP possesses significant affinity for the 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 3 , and 5-HT 7 , as well as the SERT (serotonin transporter). It also has some affinity for α 1 -adrenergic, α 2 -adrenergic, H 1 , I 1 (Imidazoline receptor), and NET (norepinephrine transporter). It behaves as an [agonist](https://psychonautwiki.org/wiki/Agonist) at most serotonin receptors. mCPP has been shown to act not only as a serotonin reuptake inhibitor but as a serotonin releasing agent as well.

mCPP's strongest actions are at the 5-HT 2B and 5-HT 2C receptors and its discriminative cue is mediated primarily by 5-HT 2C . Its negative effects such as [anxiety](https://psychonautwiki.org/wiki/Anxiety) , [headaches](https://psychonautwiki.org/wiki/Headache) , and [appetite loss](/w/index.php?title=Anorexia_(symptom)&action=edit&redlink=1) are likely mediated by its actions on the 5-HT 2C receptor. Other effects of mCPP include [nausea](https://psychonautwiki.org/wiki/Nausea) , hypoactivity, and penile erection, the latter two the result of increased 5-HT 2C activity and the former likely via 5-HT 3 stimulation.

mCPP acts as a partial agonist of the human 5-HT 2C receptor but as an antagonist of the human 5-HT 2A and 5-HT 2B receptors. In accordance with its lack of agonism towards the human 5-HT 2A receptor, there are no reports that mCPP produces [hallucinogenic](https://psychonautwiki.org/wiki/Hallucinogen) effects in humans.

mCPP is an active metabolite of the antidepressant trazodone.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** - The particular style of stimulation which mCPP presents can be described as forced. This means that, at higher dosages, it becomes difficult or impossible to keep still as jaw clenching, involuntarily bodily shakes and vibrations become present, resulting in extreme shaking of the entire body, unsteadiness of the hands, and a general lack of motor control.
- **[Decreased libido](https://psychonautwiki.org/wiki/Decreased_libido)**
- **[Difficulty urinating](https://psychonautwiki.org/wiki/Difficulty_urinating)**
- **[Nausea](https://psychonautwiki.org/wiki/Nausea)**
- **[Pupil dilation](https://psychonautwiki.org/wiki/Pupil_dilation)**
- **[Appetite suppression](https://psychonautwiki.org/wiki/Appetite_suppression)**
- **[Headaches](https://psychonautwiki.org/wiki/Headaches)**
- **[Abnormal heartbeat](https://psychonautwiki.org/wiki/Abnormal_heartbeat)**
- **[Perception of bodily heaviness](https://psychonautwiki.org/wiki/Perception_of_bodily_heaviness)**
- **[Dehydration](https://psychonautwiki.org/wiki/Dehydration)**
- **[Teeth grinding](https://psychonautwiki.org/wiki/Teeth_grinding)**
- **[Temporary erectile dysfunction](https://psychonautwiki.org/wiki/Temporary_erectile_dysfunction)**
- **[Vasoconstriction](https://psychonautwiki.org/wiki/Vasoconstriction)**
- **[Increased bodily temperature](https://psychonautwiki.org/wiki/Increased_bodily_temperature)** ### Cognitive effects
 
- - **[Dysphoria](https://psychonautwiki.org/wiki/Cognitive_dysphoria)** - While this substance can induce a mild euphoria at low doses, mCPP is generally considered to be unpleasant and dysphoric at common and high doses.
- **[Anxiety](https://psychonautwiki.org/wiki/Anxiety)**
- **[Feelings of impending doom](https://psychonautwiki.org/wiki/Feelings_of_impending_doom)**
- **[Depression](https://psychonautwiki.org/wiki/Depression)** ### Visual effects
 
- - **[Drifting](https://psychonautwiki.org/wiki/Drifting)**
- **[Tracers](https://psychonautwiki.org/wiki/Tracers)**
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: mCPP](https://erowid.org/experiences/subs/exp_mCPP.shtml)

## Toxicity and harm potential

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this drug.

### Tolerance and addiction potential

mCPP is not known to be addictive, but there are not any studies exclusively on its addiction potential.

### Dangerous interactions

mCPP is metabolized by cytochrome P450 2D6 , and concurrently taking inhibitors of that enzyme results in increased serum levels of mCPP. Commonly encounter inhibitors of CYP2D6 include ciprofloxacin, bupropion (Wellbutrin), fluoxetine (Prozac) and grapefruit juice.

***Warning:*** *Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).*

*Always conduct independent research (e.g. [Google](https://www.google.com) , [DuckDuckGo](https://www.duckduckgo.com) , [PubMed](https://pubmed.ncbi.nlm.nih.gov/) ) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from [TripSit](https://combo.tripsit.me) .*

- **[25x-NBOMe](https://psychonautwiki.org/wiki/25x-NBOMe) & [25x-NBOH](https://psychonautwiki.org/wiki/25x-NBOH)** - 25x compounds are highly stimulating and physically straining. Combinations with MCPP should be strictly avoided due to the risk of excessive [stimulation](https://psychonautwiki.org/wiki/Stimulation) and heart strain. This can result in [increased blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure) , [vasoconstriction](https://psychonautwiki.org/wiki/Vasoconstriction) , panic attacks, [thought loops](https://psychonautwiki.org/wiki/Thought_loops) , [seizures](https://psychonautwiki.org/wiki/Seizures) , and heart failure in extreme cases.
- **[Alcohol](https://psychonautwiki.org/wiki/Alcohol)** - Combining alcohol with [stimulants](https://psychonautwiki.org/wiki/Stimulants) can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's [depressant](https://psychonautwiki.org/wiki/Depressant) effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the [depressant](https://psychonautwiki.org/wiki/Depressant) effects will be left unopposed, which can result in blackouts and severe [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) . If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
- **[DXM](https://psychonautwiki.org/wiki/DXM)** - Combinations with DXM should be avoided due to its inhibiting effects on [serotonin](https://psychonautwiki.org/wiki/Serotonin) and [norepinephrine](https://psychonautwiki.org/wiki/Norepinephrine) reuptake. There is an increased risk of [panic attacks](https://psychonautwiki.org/wiki/Panic_attacks) and hypertensive crisis, or [serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) with serotonin releasers ( [MDMA](https://psychonautwiki.org/wiki/MDMA) , [methylone](https://psychonautwiki.org/wiki/Methylone) , [mephedrone](https://psychonautwiki.org/wiki/Mephedrone) , etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
- **[MDMA](https://psychonautwiki.org/wiki/MDMA)** - Any neurotoxic effects of MDMA are likely to be increased when other [stimulants](https://psychonautwiki.org/wiki/Stimulants) are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
- **[MXE](https://psychonautwiki.org/wiki/MXE)** - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of [mania](https://psychonautwiki.org/wiki/Mania) and [psychosis](https://psychonautwiki.org/wiki/Psychosis) .
- **[Dissociatives](https://psychonautwiki.org/wiki/Dissociatives)** - Both classes carry a risk of [delusions](https://psychonautwiki.org/wiki/Delusions) , [mania](https://psychonautwiki.org/wiki/Mania) and [psychosis](https://psychonautwiki.org/wiki/Psychosis) , and these risk may be multiplied when combined.
- **[Stimulants](https://psychonautwiki.org/wiki/Stimulants)** - MCPP may be dangerous to combine with other [stimulants](https://psychonautwiki.org/wiki/Stimulants) like [cocaine](https://psychonautwiki.org/wiki/Cocaine) as they can [increase one's heart rate](https://psychonautwiki.org/wiki/Increased_heart_rate) and [blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure) to dangerous levels.
- **[Tramadol](https://psychonautwiki.org/wiki/Tramadol)** - Tramadol is known to lower the seizure threshold and combinations with stimulants may further increase this risk.

- **[MAOIs](https://psychonautwiki.org/wiki/MAOIs)** - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include [syrian rue](https://psychonautwiki.org/wiki/Syrian_rue) , [banisteriopsis caapi](https://psychonautwiki.org/wiki/Banisteriopsis_caapi) , and some [antidepressants](https://psychonautwiki.org/wiki/Antidepressants) .
- **Cocaine** - This combination may increase strain on the heart.

#### Serotonin syndrome risk

Combinations with the following substances can cause dangerously high [serotonin](https://psychonautwiki.org/wiki/Serotonin) levels. [Serotonin syndrome](https://psychonautwiki.org/wiki/Serotonin_syndrome) requires immediate medical attention and can be fatal if left untreated.

- **MAOIs** - Such as [banisteriopsis caapi](https://psychonautwiki.org/wiki/Banisteriopsis_caapi) , [syrian rue](https://psychonautwiki.org/wiki/Syrian_rue) , phenelzine, selegiline, and moclobemide.
- **Serotonin releasers** - Such as [MDMA](https://psychonautwiki.org/wiki/MDMA) , [4-FA](https://psychonautwiki.org/wiki/4-FA) , [methamphetamine](https://psychonautwiki.org/wiki/Methamphetamine) , [methylone](https://psychonautwiki.org/wiki/Methylone) and [αMT](https://psychonautwiki.org/wiki/%CE%91MT) .
- **SSRIs** - Such as citalopram and sertraline
- **[SNRIs](http://en.wikipedia.org/wiki/SNRIs)** - Such as [tramadol](https://psychonautwiki.org/wiki/Tramadol) and venlafaxine
- **5-HTP**

## Legal status

- **Austria** : Since January 1, 2012, mCPP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich). [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Belgium** : mCPP is a controlled substance as of October 22, 2006.
- **Brazil** : mCPP is a controlled substance ( *lista F2 da Portaria SVS/MS 344/98* ) since November 2008.
- **China** : As of October 2015, mCPP is a controlled substance in China.
- **Denmark** : mCPP is a controlled substance as of December 3, 2005.
- **Finland** : mCPP is a controlled substance. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Germany** : mCPP is controlled under Anlage II BtMG ( *Narcotics Act, Schedule II* ) as of March 1, 2007. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- **Greece** : mCPP is a controlled substance as of January 20, 2005.
- **Hungary** : mCPP is a controlled substance as of January 1, 2006.
- **Japan** : mCPP is a controlled substance since 2006. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Lithuania** : mCPP is a controlled substance as of July 1, 2006.
- **Norway** : mCPP is a controlled substance. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Poland** : mCPP is a controlled substance. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Russia** : mCPP is a controlled substance. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Sweden** : mCPP is a controlled substance. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Switzerland** : mCPP is a controlled substance specifically named under Verzeichnis D.
- **United Kingdom** : mCPP is a Class C, Schedule 4 (Part 1) drug in the United Kingdom.
- **United States** : mCPP is unscheduled in the United States, but could be considered an analogue of benzylpiperazine if it is sold for human consumption. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Stimulant](https://psychonautwiki.org/wiki/Stimulant)
- [Entactogen](https://psychonautwiki.org/wiki/Entactogen)
- [Benzylpiperazine](/w/index.php?title=Benzylpiperazine&action=edit&redlink=1)

## External links

- [mCPP (Wikipedia)](https://en.wikipedia.org/wiki/Meta-Chlorophenylpiperazine)
- [mCPP (Erowid Vault)](https://erowid.org/chemicals/mcpp/)
- [mCPP (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=806)

## References
1. ↑ Pollard, C. B., Wicker, T. H. (April 1954).["Derivatives of Piperazine. XXIV. Synthesis of 1-Arylpiperazines and Amino Alcohol Derivatives"](https://pubs.acs.org/doi/abs/10.1021/ja01636a034).*Journal of the American Chemical Society*.**76**(7): 1853–1855.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1021/ja01636a034](//doi.org/10.1021%2Fja01636a034).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0002-7863](//www.worldcat.org/issn/0002-7863).
2. ↑ Kennett, G. A., Whitton, P., Shah, K., Curzon, G. (30 May 1989). "Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists".*European Journal of Pharmacology*.**164**(3): 445–454.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0014-2999(89)90252-5](//doi.org/10.1016%2F0014-2999%2889%2990252-5).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0014-2999](//www.worldcat.org/issn/0014-2999).
3. ↑ Leone, M., Attanasio, A., Croci, D., Filippini, G., D’Amico, D., Grazzi, L., Nespolo, A., Bussone, G. (12 July 2000). "The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study".*Neurology*.**55**(1): 136–139.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1212/wnl.55.1.136](//doi.org/10.1212%2Fwnl.55.1.136).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0028-3878](//www.worldcat.org/issn/0028-3878).
4. ↑ Bossong, M., Brunt, T., Van Dijk, J., Rigter, S., Hoek, J., Goldschmidt, H., Niesink, R. (September 2010).["mCPP: an undesired addition to the ecstasy market"](http://journals.sagepub.com/doi/10.1177/0269881109102541).*Journal of Psychopharmacology*.**24**(9): 1395–1401.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1177/0269881109102541](//doi.org/10.1177%2F0269881109102541).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0269-8811](//www.worldcat.org/issn/0269-8811).
5. ↑ 5.0 5.1 5.2 Roth, BL; Driscol, J.["PDSP Ki Database"](https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testDDRadio=testDDRadio&testLigandDD=1827&testLigand=&refDDRadio=refDDRadio&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query).*Psychoactive Drug Screening Program (PDSP)*. University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
6. ↑ Silverstone PH, Rue JE, Franklin M, et al. (September 1994). "The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers".*International Clinical Psychopharmacology*.**9**(3): 173–8.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1097/00004850-199409000-00005](//doi.org/10.1097%2F00004850-199409000-00005).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[7814826](//www.ncbi.nlm.nih.gov/pubmed/7814826).
7. ↑ Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S (August 1979). "Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats".*Naunyn-Schmiedeberg's Archives of Pharmacology*.**308**(2): 159–63.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF00499059](//doi.org/10.1007%2FBF00499059).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[503247](//www.ncbi.nlm.nih.gov/pubmed/503247).
8. ↑ Odagaki Y, Toyoshima R, Yamauchi T (May 2005). "Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding".*Journal of Psychopharmacology (Oxford, England)*.**19**(3): 235–41.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1177/0269881105051526](//doi.org/10.1177%2F0269881105051526).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[15888508](//www.ncbi.nlm.nih.gov/pubmed/15888508).
9. ↑ Pettibone DJ, Williams M (May 1984). "Serotonin-releasing effects of substituted piperazines in vitro".*[Biochemical Pharmacology](/w/index.php?title=Biochemical_Pharmacology_(journal)&action=edit&redlink=1)*.**33**(9): 1531–5.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0006-2952(84)90424-6](//doi.org/10.1016%2F0006-2952%2884%2990424-6).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[6610423](//www.ncbi.nlm.nih.gov/pubmed/6610423).
10. ↑ Callahan PM, Cunningham KA (May 1994). "Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP)".*European Journal of Pharmacology*.**257**(1–2): 27–38.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0014-2999(94)90690-4](//doi.org/10.1016%2F0014-2999%2894%2990690-4).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[8082704](//www.ncbi.nlm.nih.gov/pubmed/8082704).
11. ↑ Gommans J, Hijzen TH, Maes RA, Olivier B (June 1998).["Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action"](https://web.archive.org/web/20020112104011/http://link.springer.de/link/service/journals/00213/bibs/8137003/81370292.htm).*Psychopharmacology*.**137**(3): 292–302.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s002130050622](//doi.org/10.1007%2Fs002130050622).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[9683007](//www.ncbi.nlm.nih.gov/pubmed/9683007). Archived from[the original](http://link.springer.de/link/service/journals/00213/bibs/8137003/81370292.htm)on 2002-01-12.
12. ↑ Kennett GA, Whitton P, Shah K, Curzon G (May 1989). "Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists".*European Journal of Pharmacology*.**164**(3): 445–54.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0014-2999(89)90252-5](//doi.org/10.1016%2F0014-2999%2889%2990252-5).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[2767117](//www.ncbi.nlm.nih.gov/pubmed/2767117).
13. ↑ Kennett GA, Curzon G (1988). "Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors".*Psychopharmacology*.**96**(1): 93–100.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF02431539](//doi.org/10.1007%2FBF02431539).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[2906446](//www.ncbi.nlm.nih.gov/pubmed/2906446).
14. ↑ Kennett GA, Curzon G (May 1988).["Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors"](//www.ncbi.nlm.nih.gov/pmc/articles/PMC1853919).*[British Journal of Pharmacology](/w/index.php?title=British_Journal_of_Pharmacology&action=edit&redlink=1)*.**94**(1): 137–47.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.1476-5381.1988.tb11508.x](//doi.org/10.1111%2Fj.1476-5381.1988.tb11508.x).[PMC](http://en.wikipedia.org/wiki/PubMed_Central)[1853919](//www.ncbi.nlm.nih.gov/pmc/articles/PMC1853919).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[3401632](//www.ncbi.nlm.nih.gov/pubmed/3401632).
15. ↑ Kłodzińska A, Jaros T, Chojnacka-Wójcik E, Maj J (1989). "Exploratory hypoactivity induced by m-trifluoromethylphenylpiperazine (TFMPP) and m-chlorophenylpiperazine (m-CPP)".*Journal of Neural Transmission. Parkinson's Disease and Dementia Section*.**1**(3): 207–18.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF02248670](//doi.org/10.1007%2FBF02248670).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[2775468](//www.ncbi.nlm.nih.gov/pubmed/2775468).
16. ↑ Walsh AE, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ (September 1994). "m-Chlorophenylpiperazine decreases food intake in a test meal".*Psychopharmacology*.**116**(1): 120–2.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF02244883](//doi.org/10.1007%2FBF02244883).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[7862925](//www.ncbi.nlm.nih.gov/pubmed/7862925).
17. ↑ Stancampiano R, Melis MR, Argiolas A (August 1994). "Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission".*European Journal of Pharmacology*.**261**(1–2): 149–55.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/0014-2999(94)90313-1](//doi.org/10.1016%2F0014-2999%2894%2990313-1).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[8001637](//www.ncbi.nlm.nih.gov/pubmed/8001637).
18. ↑ 18.0 18.1 Nelson DL, Lucaites VL, Wainscott DB, Glennon RA (1999). "Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors".*Naunyn Schmiedebergs Arch. Pharmacol*.**359**(1): 1–6.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/pl00005315](//doi.org/10.1007%2Fpl00005315).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[9933142](//www.ncbi.nlm.nih.gov/pubmed/9933142).
19. ↑ Thomas DR, Gager TL, Holland V, Brown AM, Wood MD (1996). "m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor".*NeuroReport*.**7**(9): 1457–60.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1097/00001756-199606170-00002](//doi.org/10.1097%2F00001756-199606170-00002).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[8856697](//www.ncbi.nlm.nih.gov/pubmed/8856697).
20. ↑ Fong, M. H., Garattini, S., Caccia, S. (12 April 2011).["1- m -Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole"](https://academic.oup.com/jpp/article/34/10/674/6198170).*Journal of Pharmacy and Pharmacology*.**34**(10): 674–675.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/j.2042-7158.1982.tb04701.x](//doi.org/10.1111%2Fj.2042-7158.1982.tb04701.x).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[2042-7158](//www.worldcat.org/issn/2042-7158).
21. ↑ Rotzinger, S., Fang, J., Coutts, R. T., Baker, G. B. (1 December 1998).["Human CYP2D6 and metabolism of m-chlorophenylpiperazine"](https://www.biologicalpsychiatryjournal.com/article/S0006-3223(97)00483-6/fulltext).*Biological Psychiatry*.**44**(11): 1185–1191.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0006-3223(97)00483-6](//doi.org/10.1016%2FS0006-3223%2897%2900483-6).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0006-3223](//www.worldcat.org/issn/0006-3223).
22. ↑ P450 Drug Interaction Table | [http://medicine.iupui.edu/CLINPHARM/ddis/main-table](http://medicine.iupui.edu/CLINPHARM/ddis/main-table)
23. ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol".*Journal of Medical Toxicology*.**5**(2): 63–67.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF03161089](//doi.org/10.1007%2FBF03161089).[eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN)[1937-6995](//www.worldcat.org/issn/1937-6995).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1556-9039](//www.worldcat.org/issn/1556-9039).[OCLC](http://en.wikipedia.org/wiki/OCLC)[163567183](//www.worldcat.org/oclc/163567183).
24. ↑ Gillman, P. K. (2005).["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext).*British Journal of Anaesthesia*.**95**(4): 434–441.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210).[eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN)[1471-6771](//www.worldcat.org/issn/1471-6771).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0007-0912](//www.worldcat.org/issn/0007-0912).[OCLC](http://en.wikipedia.org/wiki/OCLC)[01537271](//www.worldcat.org/oclc/01537271).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).
25. ↑ Gillman, P. K. (2005).["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext).*British Journal of Anaesthesia*.**95**(4): 434–441.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210).[eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN)[1471-6771](//www.worldcat.org/issn/1471-6771).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0007-0912](//www.worldcat.org/issn/0007-0912).[OCLC](http://en.wikipedia.org/wiki/OCLC)[01537271](//www.worldcat.org/oclc/01537271).[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).
26. ↑ ["BELGIUM: New substances controlled include mCPP and khat"](http://www.emcdda.europa.eu//html.cfm//index5176EN.html?sLanguageISO=EN&nNodeID=5176&pluginMethod=eldd.shownewsdetails&id=20/12/2006BELGIUM:+New+substances+controlled+include+mCPP+and+khat). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Retrieved December 28, 2019.
27. ↑ ["MCPP é incluída na lista de substâncias psicotrópicas"](https://web.archive.org/web/20110719081356/http://www.anvisa.gov.br/divulga/noticias/2008/051108_2.htm)(in Portuguese). Agência Nacional de Vigilância Sanitária. Archived from[the original](http://www.anvisa.gov.br/divulga/noticias/2008/051108_2.htm)on July 19, 2011. Retrieved December 28, 2019.
28. ↑ ["关于印发《非药用类麻醉药品和精神药品列管办法》的通知"](http://www.sfda.gov.cn/WS01/CL0056/130753.html)(in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
29. ↑ 29.0 29.1 29.2 29.3 ["Europol–EMCDDA Active Monitoring Report on a new psychoactive substance: 1-(3-chlorophenyl)piperazine (mCPP)"](http://www.emcdda.europa.eu/system/files/publications/362/downloads/Europol-EMCDDA_Active_Monitoring_Report_mCPP_290307.pdf)(PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). December 2005. Retrieved April 19, 2020.
30. ↑ ["Anlage II BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 25, 2019.
31. ↑ ["Zwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften"](http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl107s0154.pdf)(PDF)(in German). Bundesanzeiger Verlag. Retrieved December 28, 2019.
32. ↑ ["§ 29 BtMG"](https://www.gesetze-im-internet.de/btmg_1981/__29.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 25, 2019.
33. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
34. ↑ [List of most commonly encountered drugs currently controlled under the misuse of drugs legislation](https://www.gov.uk/government/publications/controlled-drugs-list--2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation)NewPP limit report Cached time: 20251218075527 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.028 seconds CPU time usage: 0.449 seconds Real time usage: 0.972 seconds Preprocessor visited node count: 2441/1000000 Post‐expand include size: 138618/2097152 bytes Template argument size: 5882/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 52767/5000000 bytes Lua time usage: 0.440/7 seconds Lua virtual size: 8.49 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 840.186 1 -total 53.10% 446.127 23 Template:Cite_journal 13.72% 115.247 8 Template:Citation_needed 11.64% 97.810 9 Template:Cite_web 7.94% 66.740 1 Template:Fix 7.74% 65.029 1 Template:SubstanceBox/MCPP 7.32% 61.483 1 Template:SubstanceBox 7.30% 61.327 2 Template:Category_handler 2.60% 21.842 1 Template:Effects/base 2.23% 18.731 1 Template:Effect_list